Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Dental Health in Children with Sickle Cell DiseaseWhat is Sickle Cell Disease? Sickle Cel...
-
Shelley Crary, MD, MSDr. Shelley Crary received her undergrad...
-
Children’s Healthcare of Atlanta Sickle Cell Disease ProgramChildren's Healthcare of Atlanta's Sickl...
-
Edward J. Benz Jr., MDDr. Benz graduated from Harvard Medical ...
-
Wake Forest University Sickle Cell Center of ExcellenceWake Forest School of Medicine has serve...
-
Foundation For Sickle Cell Disease ResearchThe Foundation for Sickle Cell Disease R...
-
Flying doctor takes to the skies after sister’s deathOlamide Orekunrin was studying to become...
